Compare CMP & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CMP | PRME |
|---|---|---|
| Founded | 1993 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Medicinal Chemicals and Botanical Products |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 553.2M |
| IPO Year | 2003 | 2022 |
| Metric | CMP | PRME |
|---|---|---|
| Price | $24.87 | $3.16 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $21.50 | $7.56 |
| AVG Volume (30 Days) | 376.6K | ★ 2.6M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ 0.59 | N/A |
| Revenue | N/A | ★ $4,632,000.00 |
| Revenue This Year | N/A | $7.06 |
| Revenue Next Year | $1.29 | $47.01 |
| P/E Ratio | $43.44 | ★ N/A |
| Revenue Growth | N/A | ★ 55.28 |
| 52 Week Low | $16.40 | $2.67 |
| 52 Week High | $34.50 | $6.94 |
| Indicator | CMP | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 47.08 |
| Support Level | $24.49 | $3.16 |
| Resistance Level | $25.80 | $3.69 |
| Average True Range (ATR) | 0.88 | 0.23 |
| MACD | 0.21 | -0.02 |
| Stochastic Oscillator | 43.75 | 21.05 |
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.